| TG THERAPEUTICS DL -,001 |
| USA |
| Gesundheit |
| US88322Q1085 / A1JXW7 |
| NKB2 (Frankfurt) / TGTX (NASDAQ) |
| FRA:NKB2, ETR:NKB2, NKB2:GR, NASDAQ:TGTX |
| - |
| http://www.tgtherapeutics.. |
|
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases, including malignancies and autoimmune disorders, in the United Stat..
>Volltext.. |
| 5112.26 Mio. EUR |
| 5319.21 Mio. EUR |
| 601.71 Mio. EUR |
| 129.78 Mio. EUR |
| 396.84 Mio. EUR |
| 2.73 EUR |
| 647.42 Mio. EUR |
| 379.92 Mio. EUR |
| - |
| 2.75 |
| 69.72% |
| 1004.76% |
| - |
| - |
| - |
| - |
| TG THERAPEUTICS, TG THERAPEUTIC, TG THERA |
| 27.05.26 |
|
||||
|
||||
|
||||
|